June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Two Japanese families of pigmented paravenous chorioretinal atrophy due to HK1 gene mutation
Author Affiliations & Notes
  • SHIGERU SATO
    Ophthalmology, Osaka Daigaku, Suita, Osaka, Japan
    Health Sciences, Osaka Daigaku, Suita, Osaka, Japan
  • Takeshi Morimoto
    Ophthalmology, Osaka Daigaku, Suita, Osaka, Japan
  • Takashi Fujikado
    center for information and neural networks, Osaka Daigaku, Suita, Osaka, Japan
  • Sayaka Tanaka
    Ophthalmology, Osaka Daigaku, Suita, Osaka, Japan
  • Motokazu Tsujikawa
    Health Sciences, Osaka Daigaku, Suita, Osaka, Japan
    Ophthalmology, Osaka Daigaku, Suita, Osaka, Japan
  • Kohji Nishida
    Ophthalmology, Osaka Daigaku, Suita, Osaka, Japan
  • Footnotes
    Commercial Relationships   SHIGERU SATO None; Takeshi Morimoto None; Takashi Fujikado None; Sayaka Tanaka None; Motokazu Tsujikawa None; Kohji Nishida None
  • Footnotes
    Support  JSPS KAKENHI Grant Number JP22K09833
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 4540. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      SHIGERU SATO, Takeshi Morimoto, Takashi Fujikado, Sayaka Tanaka, Motokazu Tsujikawa, Kohji Nishida; Two Japanese families of pigmented paravenous chorioretinal atrophy due to HK1 gene mutation. Invest. Ophthalmol. Vis. Sci. 2023;64(8):4540.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The pigmented paravenous chorioretinal atrophy (PPRCA) is a rare disease first reported in 1937 as retino-choroiditis radiata and diagnosed by the presence of chorioretinal atrophy and pigment accumulation along the retinal veins. As a cause of PPRCA, crumbs homolog 1 gene mutation has been reported in some families. Because a Caucasian case of PPRCA due to Hexokinase 1 (HK1) mutation was recently reported, we re-examined Japanese cases diagnosed with RP79 due to HK1 mutation.

Methods : This study was conducted according to the Declaration of Helsinki and approval of the ethical committee (No.719-2) was obtained. We first extracted RP79 patients (HK1: Glu847Lys) from our cohort of hereditary retinal degenerations (IRDs), which analyzed genetically, and then identified two Japanese families. All participants underwent complete ophthalmic examinations, including ultra-widefield retinal imaging (UWFI). For sequencing, Illumina's Hiseq 2500 Platform was used. HK1 mutation (Glu847Lys) was validated by PCR direct sequence with Sanger’s method.

Results : Case 1: A 60-year-old Japanese woman complained metamorphopsia. Ophthalmic examination revealed best-corrected visual acuity (BCVA) in decimal units was 1.0 in each eye. UWFI revealed symmetrical nasal predominant chorioretinal atrophy surrounding the macula and pigment aggregation consistent with the atrophic lesion. In addition, degeneration was seen along the retinal vessels with starfish-like protrusions. Genetic testing did not detect any mutations other than HK1(Glu847Lys)that are candidates for genes responsible for IRDs.
Case 2: A 75-year-old Japanese man have already reported as RP79 (Ophthalmic genetics, 2019). His BCVA was 1.0 on the right and 0.8 on the left. UWFI revealed symmetrical retinal degeneration with starfish-like projections along retinal vessels avoiding the macula. The characteristics of this case were very similar to those of Case 1.

Conclusions : In this study, we re-examined two cases of RP79 due to HK1 mutation in our cohort. Detailed examination revealed chorioretinal atrophy and pigment clumping with starfish-like protrusions along the veins in both cases. The phenotype of our Japanese cases was very similar with a Caucasian reported earlier showing macular-sparing degeneration and PPRCA findings. The phenotypic similarities across races may provide insight into the pathogenesis of retinal degeneration caused by HK1 mutations.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×